Fate Therapeutics Inc (FATE)
5.265
-0.22
(-3.92%)
USD |
NASDAQ |
Mar 28, 16:00
5.20
-0.06
(-1.23%)
After-Hours: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 516.82M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -85.58% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 5.294 |
| Price to Book Value | 1.068 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 96.39% |
News
Headline
Wire
Time (ET)
MT Newswires
03/27 12:03
Globe Newswire
03/22 10:30
PR Newswire
03/22 05:45
Globe Newswire
03/21 18:50
Globe Newswire
03/21 11:40
PR Newswire
03/21 05:45
Globe Newswire
03/20 13:04
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 05/04/2023* | 17:00 EST | Earnings Call | Q1 2023 | -- | -- | -- | |
| 05/04/2023* | -- | Results | Q1 2023 | -- | -0.60 | -- | |
| 02/28/2023 | 17:00 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
| 02/28/2023 | -- | Results | Q4 2022 | -0.58 | -0.85 | 32.01% | |
| 11/03/2022 | 17:00 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 11/03/2022 | -- | Results | Q3 2022 | -0.86 | -0.87 | 0.73% | |
| 08/03/2022 | 17:00 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 08/03/2022 | -- | Results | Q2 2022 | -0.78 | -0.81 | 4.08% |
*Estimated Date/Time
Earnings
Profile
Edit
| Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients. |
| URL | https://www.fatetherapeutics.com |
| Investor Relations URL | https://ir.fatetherapeutics.com/ |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | May. 04, 2023 (est.) |
| Last Earnings Release | Feb. 28, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 27, 2023.
Fundamentals
| Revenue (TTM) | 96.30M |
| Total Expenses (TTM) | 404.69M |
| Net Income (TTM) | -281.72M |
| Total Assets (Quarterly) | 705.56M |
| Total Liabilities (Quarterly) | 221.62M |
| Shareholders Equity (Quarterly) | 483.94M |
| Cash from Operations (TTM) | -248.21M |
| Cash from Investing (TTM) | 166.75M |
| Cash from Financing (TTM) | 9.207M |
Ratings
Profile
Edit
| Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients. |
| URL | https://www.fatetherapeutics.com |
| Investor Relations URL | https://ir.fatetherapeutics.com/ |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | May. 04, 2023 (est.) |
| Last Earnings Release | Feb. 28, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Top Fund Holders
| Symbol | Dollars Invested | % Weight |
|---|---|---|
| CGARDX | 352.00 USD | 3.52% |
| XDNA.TO | 162426.0 USD | 3.27% |
| F00001DFE6 | 312.00 USD | 3.12% |
| XBI | 72.03M USD | 1.11% |
| CARKCX | 90.00 USD | 0.90% |
| LABU | 7.476M USD | 0.84% |
| F00001ENL6 | 82.00 USD | 0.82% |
| CARKBX | 76.00 USD | 0.76% |
| PTL030 | 14196.00 USD | 0.74% |
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| FATE Tweets |